United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil (remestemcel-L), the first mesenchymal stromal cell (MSC) ther ...